Trial Profile
A Phase IIA Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Farudodstat (Primary) ; Azacitidine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms ASLAN003-003
- Sponsors ASLAN Pharmaceuticals
- 22 Nov 2019 Status changed from recruiting to completed, according to an ASLAN Pharmaceuticals media release.
- 29 Apr 2019 According to an ASLAN Pharmaceuticals media release, the part 1 readout of this study is expected in the second quarter of 2019.
- 22 Mar 2019 According to an ASLAN Pharmaceuticals media release, the company completed third cohort and started dosing the fourth cohort in the study.